
Opinion|Videos|September 19, 2024
Results of the AGAVE-201 Study
Panelists discuss what the AGAVE-201 study displayed.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
Real-World Data Show T-DXd Activity in HER2-Mutant NSCLC
3
Durable Responses Seen With Cretostimogene in BCG-Unresponsive NMIBC
4
FDA Grants Fast Track Designation to ISM6331 for Advanced Mesothelioma
5
























